Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00610883 · ClinicalTrials.gov registry record · Phase 2
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00610883: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00610883 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00610883, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts: * Induction ends on day 19 * Consolidation ends on day 38 or 42 * Maintenance may include up to 6 cycles
Interventions
- DRUG LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 1990-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00610883
The ClinicalTrials.gov registry entry for NCT00610883 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU is the first listed.
NCT00610883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00610883 about?
NCT00610883 is a clinical study titled "LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma". Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months. To aggressively treat this cancer this study uses effective drugs in three parts: * Induction ends on day 19 *...
What is the current status of trial NCT00610883?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 1990-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00610883?
The interventions under investigation include: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU (DRUG).
Who is sponsoring clinical trial NCT00610883?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.